These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9349747)

  • 21. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy.
    Parsons JK; Carter HB; Platz EA; Wright EJ; Landis P; Metter EJ
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2257-60. PubMed ID: 16172240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.
    Zhou CK; Stanczyk FZ; Hafi M; Veneroso CC; Lynch B; Falk RT; Niwa S; Emanuel E; Gao YT; Hemstreet GP; Zolfghari L; Carroll PR; Manyak MJ; Sesterhenn IA; Levine PH; Hsing AW; Cook MB
    Prostate; 2017 Dec; 77(16):1573-1582. PubMed ID: 28971497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men.
    Trifiro MD; Parsons JK; Palazzi-Churas K; Bergstrom J; Lakin C; Barrett-Connor E
    BJU Int; 2010 Jun; 105(11):1554-9. PubMed ID: 20002438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study.
    Heikkilä R; Aho K; Heliövaara M; Hakama M; Marniemi J; Reunanen A; Knekt P
    Cancer; 1999 Jul; 86(2):312-5. PubMed ID: 10421267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediagnostic serum hormones and the risk of prostate cancer.
    Nomura A; Heilbrun LK; Stemmermann GN; Judd HL
    Cancer Res; 1988 Jun; 48(12):3515-7. PubMed ID: 3370644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis.
    Gann PH; Ma J; Giovannucci E; Willett W; Sacks FM; Hennekens CH; Stampfer MJ
    Cancer Res; 1999 Mar; 59(6):1225-30. PubMed ID: 10096552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III).
    Selvin E; Feinleib M; Zhang L; Rohrmann S; Rifai N; Nelson WG; Dobs A; Basaria S; Golden SH; Platz EA
    Diabetes Care; 2007 Feb; 30(2):234-8. PubMed ID: 17259487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
    Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
    Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The protective effect of diabetes mellitus against prostate cancer: role of sex hormones.
    Baradaran N; Ahmadi H; Salem S; Lotfi M; Jahani Y; Baradaran N; Mehrsai AR; Pourmand G
    Prostate; 2009 Dec; 69(16):1744-50. PubMed ID: 19676082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced circulating androgen bioactivity in patients with prostate cancer.
    Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
    Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormonal markers of aging in men with laryngeal carcinoma.
    Jóźków P; Medraś M; Krecicki T; Zalesska-Krecicka M
    Head Neck; 2005 Mar; 27(3):243-7. PubMed ID: 15668928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estradiol and high-dose dihydrotestosterone treatment causes changes in cynomolgus monkey prostate volume and histology identical to those caused by testosterone alone.
    Kamischke A; Weinbauer GF; Semjonow A; Lerchl A; Richter KD; Nieschlag E
    J Androl; 1999; 20(5):601-10. PubMed ID: 10520572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Kaaks R; Berrino F; Key T; Rinaldi S; Dossus L; Biessy C; Secreto G; Amiano P; Bingham S; Boeing H; Bueno de Mesquita HB; Chang-Claude J; Clavel-Chapelon F; Fournier A; van Gils CH; Gonzalez CA; Gurrea AB; Critselis E; Khaw KT; Krogh V; Lahmann PH; Nagel G; Olsen A; Onland-Moret NC; Overvad K; Palli D; Panico S; Peeters P; Quirós JR; Roddam A; Thiebaut A; Tjønneland A; Chirlaque MD; Trichopoulou A; Trichopoulos D; Tumino R; Vineis P; Norat T; Ferrari P; Slimani N; Riboli E
    J Natl Cancer Inst; 2005 May; 97(10):755-65. PubMed ID: 15900045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
    Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
    J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.
    Platz EA; Giovannucci E
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):237-53. PubMed ID: 15663987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer.
    Barrett-Connor E; Garland C; McPhillips JB; Khaw KT; Wingard DL
    Cancer Res; 1990 Jan; 50(1):169-73. PubMed ID: 2293551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.